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Abstract 
Background: 
Diabetes mellitus is one of the most serious and prevalent chronic diseases 
worldwide. One of the most common complications of diabetes in the 
lower extremity is the diabetic foot ulcer which is the precursor to ~85% of 
lower extremity amputations in persons with diabetes. 
Materials and Subjects: 
This is a case- control study which was carried out at Jabir Abu-Aliz 
Specialized Center, Khartoum State, Sudan between October 2006 and 
April 2007. 
Forty type 2 diabetes cases with septic foot (group 1 cases), 40 type 2 diabetes cases without septic 
foot (group 2 cases), and 40 healthy controls participated in this study. Their demographic data 
were collected. Serum HbA1c levels were estimated by affinity chromatography method. 
Results: 
The level of HbA1c was 9.947±1.40%, 7.908±0.45% and 6.462±0.07%. in group 1, group 2, and the 
healthy control respectively. There was significant increase in percentage level of HbA1c in group 1 
cases compared to group 2 cases and healthy control (p = 0.002, 0.001 respectively). We found very 
low correlation between fasting blood sugar and HbA1c in group 1 cases (r = + 0.331; p=0.042). 
Conclusion: 
This study indicates that the progression to the complication of foot ulcer in type 2 diabetic patients 
was correlated to the level of HbAlc.  These data may suggest a beneficial effect of considering 
measurement of HbA1c as a routine test especially for elderly diabetic patients with diabetes for 
long period. This may help to maintain blood glucose levels in the normal or near normal range and 
to provide an opportunity for patients to live out their normal life expectancies with minimal 
complications. 
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iabetes mellitus (DM) is one of the 
most serious and prevalent chronic 
diseases worldwide1.  
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It has become one of the major health 
problems with diabetic foot ulcer as one of 
the most important complications2. 
It is estimated that 15% of patients with 
diabetes will develop a lower extremity ulcer 
during the course of their disease3, 4. The 
cumulative effects of neuropathy, deformity, 
high plantar pressure, poor glucose control, 
duration of diabetes, and gender are all 
contributory factors for foot ulceration5, 6. 
While 14–20% of patients with foot ulcers 
will subsequently require an amputation, foot 
ulceration is the precursor to approximately  
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85% of the lower extremity amputations in 
persons with diabetes7, 8. 
Glycosylated hemoglobin (HbA1c) is the 
major glycohemoglobin species in human 
blood9. The percentage of HbA1c in human 
blood depends on the concentration of 
glucose, the duration of glucose exposure to 
hemoglobin, and the turnover of 
erythrocytes10. 
Although not all diabetic foot disorders can be 
prevented, it is possible to effect dramatic 
reductions in their incidence and morbidity 
through appropriate evidence-based 
prevention and management protocols. 
The objective of this study was exploiting 
HbA1c as a predictive monitoring test of 
choice to reduce complications of diabetes 
mainly septic foot in type 2 diabetic patients. 
This was done by estimating the HbAlc levels 
in type 2 diabetic patients with and without 
septic foot compared with healthy controls. 
 
Material and Methods 
Study design:  
The study is a case- control study.  
Study population and sample size:  
The study was carried out on 40 type 2 
diabetes cases with septic foot (group 1 
cases), 40 type 2 diabetes cases without septic 
foot (group 2 cases),  and 40 healthy controls. 
The ages for diabetic patients and healthy 
controls range between 50 to 70 years. 
Diabetic patients of groups (1 & 2) were 
randomly selected from the outpatient 
diabetes clinic at Jabir Abu-Aliz Specialized 
Center, Khartoum State, Sudan between  
 
 
January 2007 and April 2007. Diabetes was 
defined according to the World Health 
Organization (WHO) criteria11. Informed 
consent was obtained for each participant. 
Preparation of blood samples:  
Blood samples (5ml) were collected from the 
anticubital veins. The collected blood was 
allowed to clot for 30 minutes, and then 
centrifuged at 2000 g for 15 minutes for clear 
separation of serum.  
Estimation for glycated hemoglobin: 
Serum HbA1c levels were estimated by 
affinity chromatography method.  After 
preparing the hemolysate, where the labile 
fraction is eliminated, hemoglobins are 
retained by a cationic exchange resin. HA1c is 
specifically eluted after washing away the 
hemoglobin A1a+b  fraction1 (HbA1a+b) 12. 
Statistical analysis:  
Statistical Package for Social Studies (SPSS) 
for Windows Version 10.0 was used to 
analyse the data. All values were expressed as 
mean ± S.D. Significant differences between 
means determined by using the student t-test, 
and p value of <0.05 was considered 
statistically significant. Pearson correlation 
was applied to correlate between the fasting 




Age, gender, and duration of diabetes 
(mean±SD) of diabetic patients and healthy 
control are shown in table 1. 
The level of mean HbA1c for group 1, group 
2, and healthy control are shown in table 2 
and figure 1. 
 
Table 1. Age, gender, and duration of diabetes (mean±S.D) of patients and healthy control 
 Group 1 Group 2 Healthy control 
Age 58.11±8.2 57.01±6.12 57.68±7.1 
Gender    
          Male 50% (n=20) 47.5% (n=19) 20% (n=20) 
          Female 20% (n=20) 52.5% (n=21) 20% (n=20) 
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Table 2. The level of mean HbA1c for group 1, group 2, and healthy control 
 Group 1 cases Group 2 cases healthy control P 
HbA1c levels 9.947±1.40 7.908±0.45 6.462±0.07 0.002a     0.001b 
a group 1 cases vs. group 2 cases 




Fig 1. The level of mean HbA1c for group 1, group 2, and healthy control 
 
There was very low correlation between fasting blood sugar and HbA1c (r = + 0.331; p<0.05) in 




Fig 2. Correlation between level of HbA1c (%) and Fasting blood glucose (mgldl) 
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Type 2 DM is an important health issue in the 
world. The number of people with type 2 
diabetes, especially in developing countries, is 
expected to double in  this and next  decade 
and diabetes will be more prevalent in 
younger populations than in the past13,14. 
Foot disorders are a major source of 
morbidity and a leading cause of 
hospitalization for persons with diabetes 
mellitus. Costs of treating diabetic foot ulcers 
increase dramatically if patients require 
inpatient care and represent a substantial drain 
on health service resources. Furthermore, 
diabetic foot ulceration has a profound social 
impact with patients reporting stigma, social 
isolation, loss of social role, and 
unemployment. Quality of life is also 
reduced, and recent findings suggest that 
depression is more prevalent than in general 
diabetes15.  
At present, HbAlc measurements are accepted 
as the ‘‘golden standard’’ for assessing long-
term glycemic control. They provide an 
estimate of the average of blood glucose 
concentration during the last 2–3 months16. 
However, to our knowledge, there is no data 
concerning the relationship between HbA1c 
levels and diabetic complications mainly foot 
ulcer. From the clinical point of view, it is 
therefore interesting to analyze the HbA1c 
levels in relation to diabetes with foot ulcer. 
Our study showed that the level of HbA1c (%) 
in group 1 cases was 9.947±1.40%, while in 
group 2 cases was 7.908±0.45 compared to 
healthy control which was 6.462±0.07. There 
is significant increase in percentage level of 
HbA1c in diabetic patients with septic foot 
compared to diabetic patients without septic 
foot and healthy control (p = 0.002, 0.001 
respectively). 
Fasting blood glucose is routinely tested in 
most patients who regularly attend the 
diabetic clinics. However, in the present study 
we found very low correlation between 
fasting blood sugar and HbA1c (r = + 0.331; 
p< 0.05 “p= 0.042”) in diabetic patients with 
septic foot. A single fasting blood glucose 
measurement only gives an indication of the 
patient's immediate past (last 1 to 2 hours)  
 
condition, and may not represent the true 
status of blood glucose regulation. In contrast, 
the level of HbA1c is directly related to the 
average glucose concentration over the life-
span of the hemoglobin in the circulation. 
Since uncontrolled hyperglycemia is one of 
the most frequent risk factors for foot 
ulceration17, we may conclude that the 
progression to the complication of foot ulcer 
in type 2 diabetic patients under poor 
glycemic control is correlated to the level of 
HbAlc.  These data suggest a beneficial effect 
in terms of considering measurement of 
HbA1c as a routine test instead of fasting 
blood glucose especially for elderly diabetic 
patients with diabetes for long time. This may 
help to maintain blood glucose levels in the 
normal or near normal range and to provide 
an opportunity for patients to live out their 
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